FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to experimental oncology. Male C57BL/6 mice are initially treated with chronic neurogenic pain. After 2 weeks, a suspension of B16/F10 murine melanoma tumor cells in 0.5 ml of saline at a dilution of 1:20 is injected subcutaneously under the scapula on the left. 24 hours after inoculation of B16/F10 melanoma, mice are intraperitoneally injected with freshly isolated mitochondria from the heart of intact rats: 3.3 mg of protein per 1 animal in 0.3 ml of saline, then mitochondrial therapy is carried out daily for 21 days.
EFFECT: invention prevents the development of myocardial infarction.
1 cl, 5 dwg, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF THE MELANOMA TUMOR NODES FORMATION IN THE BODY OF EXPERIMENTAL ANIMALS | 2022 |
|
RU2796892C1 |
| METHOD FOR EXPERIMENTAL BIOTHERAPY OF B16/F10 MELANOMA | 2022 |
|
RU2779698C1 |
| METHOD FOR SELECTING MITOCHONDRIA FOR EXPERIMENTAL THERAPY OF B16-F10 MELANOMA | 2022 |
|
RU2794762C1 |
| METHOD FOR REVERSING GENETICALLY DETERMINED INHIBITION OF GROWTH OF A MALIGNANT TUMOR IN EXPERIMENT | 2019 |
|
RU2718671C1 |
| METHOD OF FORMATION OF TUMOR GROWTH IN LUNGS OF EXPERIMENTAL ANIMALS | 2023 |
|
RU2810431C1 |
| METHOD OF INDUCING GROWTH OF HUMAN COLON ADENOCARCINOMA IN ORGANS OF EXPERIMENTAL ANIMALS | 2023 |
|
RU2799251C1 |
| TARGETED NON-INVASIVE TRANSPLANTATION INTO BRAIN OF FUNCTIONALLY ACTIVE MITOCHONDRIA FOR TREATING NEURODEGENERATIVE DISEASES | 2019 |
|
RU2744453C2 |
| METHOD FOR ENHANCING THE GROWTH OF B16/F10 MELANOMA VERSUS THE GROWTH OF B16/F10 MELANOMA WITH SELF-GRAFTING AND SLOWING THE GROWTH OF LLC (LEWIS CARCINOMA) VERSUS THE GROWTH OF LLC WITH SELF-GRAFTING IN CASE OF MULTIPLE PRIMARY MALIGNANT TUMORS AGAINST THE BACKGROUND OF PRIMARY IMMUNODEFICIENCY | 2021 |
|
RU2759487C1 |
| TREATING HEART FAILURE | 2020 |
|
RU2824501C2 |
| METHOD FOR CREATING POLYNEOPLASIA WITH STIMULATION OF TUMOR GROWTH IN CONDITIONS OF PRIMARY IMMUNODEFICIENCY IN EXPERIMENT | 2021 |
|
RU2751930C1 |
